The alterations in the levels of proteins impacting the MCL-1 activity and stability, such as p-ERK1/2, BIM and NOXA, could explain the differences in pro-apoptotic response to MCL-1 inhibitors between trametinib-resistant melanoma cells grown with and without trametinib. Here, MAPK3 is linked to melanoma.